149.31
3.24%
4.69
After Hours:
149.32
0.010
+0.01%
Ascendis Pharma A S Adr stock is traded at $149.31, with a volume of 538.88K.
It is up +3.24% in the last 24 hours and up +7.84% over the past month.
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
See More
Previous Close:
$144.62
Open:
$143.69
24h Volume:
538.88K
Relative Volume:
0.96
Market Cap:
$8.91B
Revenue:
$343.51M
Net Income/Loss:
$-530.29M
P/E Ratio:
-13.19
EPS:
-11.3176
Net Cash Flow:
$-610.17M
1W Performance:
+1.85%
1M Performance:
+7.84%
6M Performance:
-1.23%
1Y Performance:
+59.45%
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Name
Ascendis Pharma A S Adr
Sector
Industry
Phone
-
Address
-
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-20-23 | Initiated | Jefferies | Buy |
Jun-14-23 | Resumed | Credit Suisse | Neutral |
Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
Oct-20-22 | Initiated | Goldman | Buy |
Aug-30-22 | Resumed | Berenberg | Buy |
Mar-28-22 | Resumed | Wedbush | Outperform |
Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
Mar-01-22 | Initiated | Citigroup | Buy |
Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-06-22 | Initiated | Cowen | Market Perform |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
Mar-11-21 | Resumed | Stifel | Buy |
Dec-17-20 | Initiated | Berenberg | Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Mar-20-20 | Initiated | Oppenheimer | Outperform |
Oct-11-19 | Initiated | Morgan Stanley | Overweight |
Mar-25-19 | Initiated | Evercore ISI | Outperform |
Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
Jun-26-18 | Initiated | Stifel | Buy |
Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
May-11-17 | Initiated | JP Morgan | Overweight |
Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Feb-09-17 | Initiated | Credit Suisse | Outperform |
Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Adr Stock (ASND) Latest News
Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish - Benzinga
Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News
Sei Investments Co. Sells 81,615 Shares of Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? - Benzinga
Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC - MarketBeat
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors - GlobeNewswire Inc.
Ascendis Pharma launches $300 million public offering - Investing.com
Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat
Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Yahoo Finance
Analyzing Edgewise Therapeutics Inc (EWTX) After Recent Trading Activity - Knox Daily
Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News
Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com
Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News
Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com India
Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating - Investing.com India
Goldman Sachs raises Ascendis Pharma stock price target on study success - Investing.com India
Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com
Barclays maintains BioMarin at Overweight with $110 target - Investing.com
Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily
Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com India
Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year - Benzinga
Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com
Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com India
Ascendis Pharma reports growth in achondroplasia trial - Investing.com India
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo - GlobeNewswire Inc.
Citi maintains buy on Ascendis with $178 target amid trial data - Investing.com
Market Insights: Ascendis Pharma A/S ADR (ASND)’s Notable Gain of 0.78, Closing at 113.81 - The Dwinnex
Ascendis Pharma A/S ADR (ASND)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Closing Figures Unveiled: Ascendis Pharma A/S ADR (ASND) Drop -1.94, Closes at 116.84 - The Dwinnex
Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com India
Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com
A better buy-in window may exist right now for Ascendis Pharma A/S ADR (ASND) - SETE News
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
TD Cowen maintains Buy on Ascendis, keeps $157 target - Investing.com
Ascendis Pharma A/S ADR (ASND) requires closer examination - US Post News
Stock Performance Spotlight: Ascendis Pharma A/S ADR (ASND) Ends the Day at 119.50, Down by -11.27 - The Dwinnex
Jefferies cuts Ascendis share price target amid hGH market pressure - Investing.com
Goldman Sachs cuts Ascendis Pharma shares target, maintains Buy rating - Investing.com
Ascendis Pharma stock target cut, retains rating amid Skytrofa sales miss - Investing.com
Earnings call: Ascendis Pharma reports mixed Q2 2024 results, forecasts growth - Investing.com
Why Ascendis Pharma Stock Tumbled by 11% Today - The Motley Fool
Biotech Makes A Bearish Move On Drug-Pricing Fiasco - Investor's Business Daily
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - SETE News
Ascendis Pharma stock tanks on earnings miss - Investing.com
Ascendis Pharma A S Adr Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):